NFKB1 and breast cancer: These findings may have important clinical implications in raising the possibility that inhibitors of the canonical NFκB pathway, as osteoanabolics may have advantages over conventional anti-resorptive agents such as bisphosphonate [49, 52] and Denosumab [53, 54] for the treatment of osteolysis in advanced breast cancer patients given that they may encourage new bone regeneration.